Brief: SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247
21/01/2026 13:01
Jan 21 (Reuters) - SCYNEXIS Inc SCYX.O: SCYNEXIS RECEIVES FDA QUALIFIED INFECTIOUS DISEASE PRODUCT (QIDP) AND FAST TRACK DESIGNATIONS FOR SCY-247 SCYNEXIS INC - TO INITIATE PHASE 1 AND 2 STUDIES OF SCY-247 IN 2026 SCYNEXIS INC - QIDP DESIGNATION ENSURES 10 YEARS MARKET EXCLUSIVITY FOR SCY-247 Source text: ID:nGNX9wStQ6 Further company coverage: SCYX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview